Microbiological Efficacy of Levofloxacin for Treatment of Community-Acquired Pneumonia Due to Chlamydia pneumoniae
- 1 May 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (5) , 1409
- https://doi.org/10.1128/aac.44.5.1409-1409.2000
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Sequencing of Gyrase and Topoisomerase IV Quinolone-Resistance-Determining Regions of Chlamydia trachomatis and Characterization of Quinolone-Resistant Mutants Obtained In VitroAntimicrobial Agents and Chemotherapy, 1998
- Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Community‐Acquired Pneumonia in Adults: Guidelines for ManagementClinical Infectious Diseases, 1998
- Microbiologic Efficacy of Azithromycin and Susceptibilities to Azithromycin of Isolates of Chlamydia pneumoniae from Adults and Children with Community-Acquired PneumoniaAntimicrobial Agents and Chemotherapy, 1998
- A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumoniaAntimicrobial Agents and Chemotherapy, 1997
- Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumoniaThe Pediatric Infectious Disease Journal, 1995